Exploratory breast cancer trial suggests a possible delay in progression
During chemotherapy, intermittent calorie restriction plus resistance exercise had longer median progression-free survival than exercise alone. The exploratory statistical approach and uncertain progression estimate leave this finding unconfirmed.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
The combined group had a longer reported median time without cancer progression, alongside better quality-of-life questionnaire results. Chemotherapy toxicity was described as low and comparable between groups. However, the trial used an exploratory significance threshold, and its progression estimate remained uncertain. These findings warrant confirmation rather than a treatment recommendation.
The adjusted progression hazard rate was 0.729 (reported interval 0.391–1.361), spanning no difference. The abstract does not identify the interval's confidence level, and larger confirmation is needed.
What researchers found
Median progression-free survival
Calorie restriction plus resistance exercise versus exercise alone during chemotherapy; p = 0.160. Overall follow-up duration was not reported.
An exploratory statistical threshold
The researchers assessed significance using a one-sided 20% threshold. This helps explain their favorable interpretation of the progression result, but the study was a screening trial rather than definitive confirmation.
Other outcomes answer different questions
The combined group also had greater weight loss and more favorable quality-of-life and anxiety/depression questionnaire changes at the reported chemotherapy assessment. These outcomes are separate from cancer progression; comparable reported toxicity does not establish comprehensive safety.
The original publication
Randomised phase-2 screening trial of intermittent energy restriction plus resistance exercise versus resistance exercise alone during chemotherapy for advanced breast cancer.
Harvie M, Pegington M, Howell A et al.
Br J Cancer · 2025
- PubMed ID
- 40745221
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.